Home Top Stories NAFDAC seeks global support to boost vaccine production in Nigeria

NAFDAC seeks global support to boost vaccine production in Nigeria

0
31
NAFDAC seeks global support to boost vaccine production in Nigeria
NAFDAC DG, Prof. Mojisola Adeyeye, discussing with the Managing Director, SKG, Dr Okey Akpa; PMG-MAN Chairman, Mr Oluwatosin Jolayemi, and other executive at the expo.

The Director General, National Agency for Food and Drug Administration and Control (NAFDAC), Prof. Mojisola Adeyeye, has sought support from international bodies to provide vaccine manufacturing facilities in Nigeria.

This was announced at the 8TH Nigeria Pharma Manufacturers Expo in collaboration with the Pharmaceutical Manufacturing Group of the Manufacturers Association of Nigeria (PMG-MAN) and PGE Expo PVT Limited.

She underlined local vaccine manufacturing as Nigeria’s major constraint to attaining WHO Maturity Level vaccine lot release.
According to her, NAFDAC has met the required standards in eight of the nine areas needed for the agency to be fully recognised for regulating medicines and vaccines. The only remaining requirement is vaccine lot release.

She urged international organisations and development partners that have supported NAFDAC over the years to contribute to the establishment of a fill-and-finish modular vaccine manufacturing facility in the country.

“We want to call on our international partners who have been of tremendous help. Without them, we wouldn’t have been here. I want to challenge them to contribute, to fill and finish Modular Vaccine manufacturing so that we can get our Vaccine Lot Release,” Adeyeye said

She added that Nigeria had the capacity to attain the WHO Maturity Level 4 status, noting that the major gap was the absence of local vaccine manufacturing.

Adeyeye said NAFDAC had already estimated the cost of establishing the required facility and would share the details with potential partners.

“It’s not going to cost too much. We will share that with you. Because we cannot afford to go back to where we used to be,” she said.

The NAFDAC boss also recalled that the country previously had vaccine manufacturing capacity, saying Nigeria needed to return to local production.

“It’s high time we went back to vaccine manufacturing,” she said.

Adeyeye also highlighted improvements in Nigeria’s pharmaceutical manufacturing sector, attributing part of the progress to efforts by NAFDAC to strengthen Good Manufacturing Practice (GMP) compliance.

She said NAFDAC inspectors conducted GMP compliance audits of more than 165 pharmaceutical companies over eight months under the agency’s GMP Roadmap initiative, funded by the United States Agency for International Development (USAID) and implemented by the United States Pharmacopoeia.

She said the initiative aimed to ensure local manufacturers focused not only on producing medicines but also on meeting quality standards.

According to Adeyeye, data from 2021 to 2025 showed that imports of products under the “5 plus 5” and Ceiling Initiative declined by 70 per cent as local manufacturers increased their capacity to produce medicines.

She attributed the progress to improved competence among NAFDAC staff and stronger regulatory systems.
“You cannot give what you don’t have,” she said.

Adeyeye noted that the agency had also gained international recognition, including becoming a member of the International Medical Device Regulators Forum in 2023, while NAFDAC’s laboratory in Yaba became WHO prequalified in September 2023.

She explained that WHO Maturity Level 3 was not a permanent status, as the global health body periodically reassesses regulatory agencies to ensure they maintain the required standards.

According to her, NAFDAC became the first regulatory agency in sub-Saharan Africa to successfully undergo the first re-benchmarking process after achieving Maturity Level 3.

She credited the progress to the efforts of local manufacturers, NAFDAC staff and other stakeholders in the pharmaceutical sector.

Speaking at the event, the Chairman of PMG-MAN, Mr Oluwatosin Jolayemi, described the expo as a major platform for pharmaceutical manufacturers, regulators, investors and development partners to showcase industry capabilities and build partnerships.

Jolayemi, who is also the managing director and chief executive officer of Daily Need Limited, commended Adeyeye for her efforts toward improving quality and GMP compliance within the pharmaceutical industry.

He said NAFDAC’s policies were beginning to transform the pharmaceutical manufacturing ecosystem but stressed that the gains needed to be sustained.

Jolayemi also called for the extension of the Federal Government’s Executive Order on pharmaceutical manufacturing incentives for another two years when it expires in March 2027.

He said achieving medicine security and pharmaceutical sovereignty would require consistent policies, investment, development of local capabilities and a predictable business environment.

The two-day expo attracted 132 participating companies from countries including Nigeria, the United States, China, Argentina, Egypt, India, Rwanda, Austria, the United Arab Emirates, France, Germany and Indonesia.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here